2024-10-22 13:33:24
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
Health/ 2023-07-22
LISCure's Phase 2 Drug Candidate Gr...

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases

ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit
Health/ 2023-07-22
ReviR Therapeutics to Present at RNA Tar...

SAN FRANCISCO,Calif.,Dec. 8,2022-- ReviR Therapeutics (ReviR),a biotechnology company developing small molecule therapies targeting RNA,toda...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release